A growing number of telehealth platforms and weight-loss clinics market "microdosing" of GLP-1 drugs like semaglutide and tirzepatide — using amounts smaller than the doses studied and approved for diabetes or obesity — for purposes ranging from "more energy" and fewer gastrointestinal side effects to vague anti-aging and longevity claims. The trend has grown fast enough that it's drawn public comment from both Eli Lilly and Novo Nordisk, as well as caution from independent researchers. This article covers what's actually known, not how to microdose, which this site does not provide guidance on.

What People Mean by "Microdosing"

In this context, microdosing generally refers to taking a GLP-1 medication at a smaller amount, a less frequent interval, or both, compared with the dose a patient would be titrated to under standard, FDA-approved dosing for diabetes or chronic weight management. Some proponents frame this as a way to get "some" benefit with fewer side effects; others frame it, more speculatively, as a wellness or longevity strategy, pointing to GLP-1 drugs' broader effects on inflammation and metabolism.

Why the Trend Has Caught On

Cost is one practical driver: brand-name GLP-1 drugs can run over $1,000 a month without insurance coverage, and a smaller amount used less often is, naturally, less expensive. Some patients also report that lower amounts caused less nausea and other GI discomfort than the doses they were prescribed, which is biologically plausible given that GI side effects from this drug class are generally dose-related. Separately, interest in GLP-1 drugs' non-weight-loss effects — on inflammation markers, on the brain's reward circuitry, and in some early research, on measures of biological aging covered elsewhere on this site — has fed speculation that a smaller, ongoing amount might offer some of those effects without the full side-effect burden of a standard regimen.

What the Evidence Actually Says

Here is the central problem: there is essentially no published clinical trial evidence establishing that doses smaller than the ones studied in FDA trials are safe or effective for any of the purposes being marketed. The large randomized trials that support semaglutide's and tirzepatide's approvals used specific, defined dose-escalation schedules; smaller or less-frequent dosing outside that schedule hasn't been systematically studied in the same way. Researchers who study this drug class, including academics quoted in recent reporting on the trend, have been direct that patient-reported anecdotes about "feeling better" on a lower amount don't establish that the approach is safe, effective, or appropriate, and that the biological mechanism behind any claimed benefit at sub-therapeutic levels remains unclear. Both Eli Lilly and Novo Nordisk have stated publicly that they have no data on the safety or efficacy of using their drugs outside approved, labeled dosing.

Where the Risk Comes From

Beyond the lack of supporting data, there's a specific safety concern tied to how a lot of microdosing is actually obtained: much of it is sold through compounding pharmacies or telehealth platforms offering "personalized" doses of compounded semaglutide or tirzepatide, rather than the FDA-approved pen devices at their labeled strengths. Compounded versions of these drugs fall outside the FDA's standard approval and manufacturing-quality process, and the agency, along with Lilly and Novo Nordisk through litigation, has raised repeated concerns about inconsistent dosing, contamination, and inaccurate marketing claims in this part of the market. A smaller, unverified dose from an unregulated source carries different, and in some ways harder-to-quantify, risks than an FDA-approved dose used off-label.

The Bottom Line

"Microdosing" GLP-1 drugs is, at this point, a consumer trend running ahead of the research, not a medically established practice. Anyone considering any change to how they take a prescribed GLP-1 medication — including taking less than prescribed, or less often — should raise that directly with their prescribing physician rather than acting on marketing claims or social media anecdotes, since dose changes made outside medical supervision can affect both safety and whether the treatment is likely to work for its intended purpose.